Karyopharm Therapeutics Inc Financials
This page shows Karyopharm Therapeutics Inc (KPTI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Karyopharm Therapeutics Inc has an operating margin of 79.0%, meaning the company retains $79 of operating profit per $100 of revenue. This strong profitability earns a score of 100/100, reflecting efficient cost management and pricing power. This is up from -82.2% the prior year.
Karyopharm Therapeutics Inc's revenue declined 99.9% year-over-year, from $145.2M to $115K. This contraction results in a growth score of 0/100.
Karyopharm Therapeutics Inc carries a low D/E ratio of 0.40, meaning only $0.40 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 96/100, indicating a strong balance sheet with room for future borrowing.
Karyopharm Therapeutics Inc's current ratio of 1.12 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 25/100, which could limit financial flexibility.
Karyopharm Therapeutics Inc converts 65.5% of revenue into free cash flow ($75K). This strong cash generation earns a score of 100/100.
Karyopharm Therapeutics Inc earns a strong 66.9% return on equity (ROE), meaning it generates $67 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 100/100.
Karyopharm Therapeutics Inc scores -485.15, below the 1.81 distress threshold. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Karyopharm Therapeutics Inc passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Karyopharm Therapeutics Inc generates $0.38 in operating cash flow ($75K OCF vs $196K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Karyopharm Therapeutics Inc earns $33.2 in operating income for every $1 of interest expense ($91K vs $3K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Karyopharm Therapeutics Inc generated $115K in revenue in fiscal year 2025. This represents a decrease of 99.9% from the prior year.
Karyopharm Therapeutics Inc's EBITDA was $91K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 100.1% from the prior year.
Karyopharm Therapeutics Inc generated $75K in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 100.1% from the prior year.
Karyopharm Therapeutics Inc reported $196K in net income in fiscal year 2025. This represents an increase of 100.3% from the prior year.
Karyopharm Therapeutics Inc earned $17.93 per diluted share (EPS) in fiscal year 2025. This represents an increase of 228.1% from the prior year.
Karyopharm Therapeutics Inc held $61K in cash against $116K in long-term debt as of fiscal year 2025.
Karyopharm Therapeutics Inc had 18M shares outstanding in fiscal year 2025. This represents a decrease of 85.5% from the prior year.
Karyopharm Therapeutics Inc's gross margin was 94.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs.
Karyopharm Therapeutics Inc's operating margin was 79.0% in fiscal year 2025, reflecting core business profitability. This is up 161.2 percentage points from the prior year.
Karyopharm Therapeutics Inc's net profit margin was 170.7% in fiscal year 2025, showing the share of revenue converted to profit. This is up 223.3 percentage points from the prior year.
Karyopharm Therapeutics Inc's ROE was 66.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Karyopharm Therapeutics Inc invested $126K in research and development in fiscal year 2025. This represents a decrease of 99.9% from the prior year.
Karyopharm Therapeutics Inc invested $142 in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 99.9% from the prior year.
KPTI Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $34.1M-22.6% | $44.0M+16.1% | $37.9M+26.4% | $30.0M-1.7% | $30.5M-21.2% | $38.8M-9.4% | $42.8M+29.2% | $33.1M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $27.7M-9.4% | $30.5M-6.8% | $32.8M-5.3% | $34.6M+4.0% | $33.3M-7.8% | $36.1M-5.8% | $38.4M+8.3% | $35.4M |
| SG&A Expenses | $22.8M-14.4% | $26.6M-6.6% | $28.5M+4.1% | $27.4M+0.6% | $27.2M-1.6% | $27.6M-11.1% | $31.1M+5.1% | $29.5M |
| Operating Income | -$17.8M-17.2% | -$15.2M+37.6% | -$24.4M+26.7% | -$33.3M-6.3% | -$31.3M-19.0% | -$26.3M+6.5% | -$28.1M+16.7% | -$33.8M |
| Interest Expense | $12.6M+14.6% | $11.0M-2.0% | $11.2M+2.1% | $11.0M-1.9% | $11.2M-1.6% | $11.4M+27.2% | $8.9M+52.1% | $5.9M |
| Income Tax | -$67K-297.1% | $34K-15.0% | $40K+11.1% | $36K+133.0% | -$109K-489.3% | $28K-58.2% | $67K-5.6% | $71K |
| Net Income | -$102.2M-208.5% | -$33.1M+11.1% | -$37.3M-58.8% | -$23.5M+23.8% | -$30.8M+4.0% | -$32.1M-234.8% | $23.8M+163.7% | -$37.4M |
| EPS (Diluted) | $-7.02 | $-3.82 | $-4.32-56.0% | $-2.77 | $-2.33+39.5% | $-3.85-29.6% | $-2.97+38.8% | $-4.85 |
KPTI Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $108.4M+12.7% | $96.2M-8.2% | $104.9M-17.9% | $127.7M-22.3% | $164.4M-13.2% | $189.5M-11.5% | $214.0M+4.7% | $204.5M |
| Current Assets | $103.1M+14.9% | $89.7M-8.3% | $97.9M-18.6% | $120.2M-23.2% | $156.5M-15.3% | $184.8M-11.4% | $208.5M+5.1% | $198.4M |
| Cash & Equivalents | $60.5M+60.7% | $37.7M-2.7% | $38.7M-0.1% | $38.8M-37.9% | $62.5M-14.2% | $72.8M-14.1% | $84.8M+176.8% | $30.6M |
| Inventory | $4.0M+1.8% | $4.0M-20.6% | $5.0M+4.7% | $4.8M+0.6% | $4.7M+1.4% | $4.7M+34.4% | $3.5M+25.5% | $2.8M |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $401.3M+9.8% | $365.5M+6.3% | $343.8M+3.1% | $333.6M-4.8% | $350.4M+0.4% | $349.1M+0.9% | $346.1M-7.3% | $373.4M |
| Current Liabilities | $92.1M+5.6% | $87.2M-12.2% | $99.2M+9.8% | $90.4M-2.1% | $92.3M+50.0% | $61.5M+6.7% | $57.6M-11.8% | $65.3M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$292.9M-8.8% | -$269.3M-12.7% | -$238.9M-16.0% | -$205.9M-10.7% | -$186.0M-16.5% | -$159.6M-20.8% | -$132.1M+21.8% | -$169.0M |
| Retained Earnings | -$1.8B-6.2% | -$1.7B-2.0% | -$1.6B-2.3% | -$1.6B-1.5% | -$1.6B-2.0% | -$1.5B-2.1% | -$1.5B+1.6% | -$1.5B |
KPTI Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$11.8M-101.8% | -$5.9M+68.7% | -$18.7M+52.0% | -$39.0M-51.0% | -$25.8M-32.7% | -$19.5M+49.5% | -$38.5M+12.0% | -$43.7M |
| Capital Expenditures | $0 | $0 | $0 | $0+100.0% | -$53K | $0 | $0-100.0% | $195K |
| Free Cash Flow | -$11.8M-101.8% | -$5.9M+68.7% | -$18.7M+52.0% | -$39.0M-50.7% | -$25.9M-33.0% | -$19.5M+49.5% | -$38.5M+12.3% | -$43.9M |
| Investing Cash Flow | $5.0M+4.1% | $4.8M-73.7% | $18.3M+19.6% | $15.3M+3.3% | $14.8M+98.0% | $7.5M-85.4% | $51.3M+133.6% | $21.9M |
| Financing Cash Flow | $29.7M | $0 | N/A | N/A | $680K | $0 | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
KPTI Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -52.4%-17.8pp | -34.6%+29.7pp | -64.3%+46.5pp | -110.8%-8.4pp | -102.4%-34.7pp | -67.8%-2.0pp | -65.7%+36.2pp | -101.9% |
| Net Margin | -299.9%-224.7pp | -75.2%+23.0pp | -98.2%-20.1pp | -78.2%+22.6pp | -100.8%-18.1pp | -82.7%-138.3pp | 55.6%+168.4pp | -112.8% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -94.3%-59.8pp | -34.4%+1.1pp | -35.5%-17.2pp | -18.4%+0.4pp | -18.7%-1.8pp | -16.9%-28.0pp | 11.1%+29.4pp | -18.3% |
| Current Ratio | 1.12+0.1 | 1.03+0.0 | 0.99-0.3 | 1.33-0.4 | 1.70-1.3 | 3.00-0.6 | 3.62+0.6 | 3.04 |
| Debt-to-Equity | -1.37-0.0 | -1.36+0.1 | -1.44+0.2 | -1.62+0.3 | -1.88+0.3 | -2.19+0.4 | -2.62-0.4 | -2.21 |
| FCF Margin | -34.7%-21.4pp | -13.3%+36.0pp | -49.3%+80.6pp | -129.9%-45.2pp | -84.7%-34.5pp | -50.2%+39.8pp | -90.0%+42.6pp | -132.6% |
Similar Companies
Frequently Asked Questions
What is Karyopharm Therapeutics Inc's annual revenue?
Karyopharm Therapeutics Inc (KPTI) reported $115K in total revenue for fiscal year 2025. This represents a -99.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Karyopharm Therapeutics Inc's revenue growing?
Karyopharm Therapeutics Inc (KPTI) revenue declined by 99.9% year-over-year, from $145.2M to $115K in fiscal year 2025.
Is Karyopharm Therapeutics Inc profitable?
Yes, Karyopharm Therapeutics Inc (KPTI) reported a net income of $196K in fiscal year 2025, with a net profit margin of 170.7%.
What is Karyopharm Therapeutics Inc's earnings per share (EPS)?
Karyopharm Therapeutics Inc (KPTI) reported diluted earnings per share of $17.93 for fiscal year 2025. This represents a 228.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Karyopharm Therapeutics Inc's EBITDA?
Karyopharm Therapeutics Inc (KPTI) had EBITDA of $91K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Karyopharm Therapeutics Inc have?
As of fiscal year 2025, Karyopharm Therapeutics Inc (KPTI) had $61K in cash and equivalents against $116K in long-term debt.
What is Karyopharm Therapeutics Inc's gross margin?
Karyopharm Therapeutics Inc (KPTI) had a gross margin of 94.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Karyopharm Therapeutics Inc's operating margin?
Karyopharm Therapeutics Inc (KPTI) had an operating margin of 79.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Karyopharm Therapeutics Inc's net profit margin?
Karyopharm Therapeutics Inc (KPTI) had a net profit margin of 170.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Karyopharm Therapeutics Inc's return on equity (ROE)?
Karyopharm Therapeutics Inc (KPTI) has a return on equity of 66.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Karyopharm Therapeutics Inc's free cash flow?
Karyopharm Therapeutics Inc (KPTI) generated $75K in free cash flow during fiscal year 2025. This represents a 100.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Karyopharm Therapeutics Inc's operating cash flow?
Karyopharm Therapeutics Inc (KPTI) generated $75K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Karyopharm Therapeutics Inc's total assets?
Karyopharm Therapeutics Inc (KPTI) had $108K in total assets as of fiscal year 2025, including both current and long-term assets.
What are Karyopharm Therapeutics Inc's capital expenditures?
Karyopharm Therapeutics Inc (KPTI) invested $142 in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Karyopharm Therapeutics Inc spend on research and development?
Karyopharm Therapeutics Inc (KPTI) invested $126K in research and development during fiscal year 2025.
How many shares does Karyopharm Therapeutics Inc have outstanding?
Karyopharm Therapeutics Inc (KPTI) had 18M shares outstanding as of fiscal year 2025.
What is Karyopharm Therapeutics Inc's current ratio?
Karyopharm Therapeutics Inc (KPTI) had a current ratio of 1.12 as of fiscal year 2025, which is considered adequate.
What is Karyopharm Therapeutics Inc's debt-to-equity ratio?
Karyopharm Therapeutics Inc (KPTI) had a debt-to-equity ratio of 0.40 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Karyopharm Therapeutics Inc's return on assets (ROA)?
Karyopharm Therapeutics Inc (KPTI) had a return on assets of 180.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Karyopharm Therapeutics Inc's Altman Z-Score?
Karyopharm Therapeutics Inc (KPTI) has an Altman Z-Score of -485.15, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Karyopharm Therapeutics Inc's Piotroski F-Score?
Karyopharm Therapeutics Inc (KPTI) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Karyopharm Therapeutics Inc's earnings high quality?
Karyopharm Therapeutics Inc (KPTI) has an earnings quality ratio of 0.38x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Karyopharm Therapeutics Inc cover its interest payments?
Karyopharm Therapeutics Inc (KPTI) has an interest coverage ratio of 33.2x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Karyopharm Therapeutics Inc?
Karyopharm Therapeutics Inc (KPTI) scores 70 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.